Nasdaq

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...

Brainlab and Precision NeuroMed Announce Strategic Partnership to Standardize and Scale Precision Drug Delivery to the Brain

New AI-Driven Planning Platform Designed to Unlock a New Class of Disease-Modifying Therapies for CNS Disorders MUNICH & REDWOOD CITY, Calif.--(BUSIN ...
Fox21Online

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional ...
Business Wire

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

MEDFORD, Mass.--(BUSINESS WIRE)--Myrobalan Therapeutics, a biotechnology company developing novel oral neurorestorative therapies to repair damage and restore neural function in high-unmet need ...
Morningstar

Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer

Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025 /PRNewswire/ -- Transneural Therapeutics, Inc. ...